Alison Dziarmaga

Oncology

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Oncology

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.